請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/54627完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 張惠雯(Hui-Wen Chang) | |
| dc.contributor.author | Cheng-Hsin Shih | en |
| dc.contributor.author | 施正心 | zh_TW |
| dc.date.accessioned | 2021-06-16T03:35:58Z | - |
| dc.date.issued | 2021 | |
| dc.date.submitted | 2021-03-31 | |
| dc.identifier.citation | Aberdein, D., Munday, J.S., Dyer, C.B., Knight, C.G., French, A.F., Gibson, I.R., 2007. Comparison of the histology and immunohistochemistry of vaccination-site and non-vaccination-site sarcomas from cats in New Zealand. N Z Vet J 55, 203-207. Aigner, P., Just, V., Stoiber, D., 2019. STAT3 isoforms: Alternative fates in cancer? Cytokine 118, 27-34. Alexander, W.S., 2002. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2, 410-416. Alexandrow, M.G., Song, L.J., Altiok, S., Gray, J., Haura, E.B., Kumar, N.B., 2012. Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur J Cancer Prev 21, 407-412. Assumpcao, A., Jark, P.C., Hong, C.C., Lu, Z., Ruetten, H.M., Heaton, C.M., Pinkerton, M.E., Pan, X., 2018. STAT3 expression and activity are up-regulated in diffuse large B cell lymphoma of dogs. J Vet Intern Med 32, 361-369. Ball, S., Li, C., Li, P.K., Lin, J., 2011. The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells. PLoS One 6, e18820. Banerji, N., Li, X., Klausner, J.S., Kapur, V., Kanjilal, S., 2002. Evaluation of in vitro chemosensitivity of vaccine-associated feline sarcoma cell lines to vincristine and paclitaxel. Am J Vet Res 63, 728-732. Barber, L.G., Sorenmo, K.U., Cronin, K.L., Shofer, F.S., 2000. Combined doxorubicin and cyclophosphamide chemotherapy for nonresectable feline fibrosarcoma. J Am Anim Hosp Assoc 36, 416-421. Bekki, H., Kohashi, K., Yamada, Y., Iura, K., Ishii, T., Maekawa, A., Otsuka, H., Yamamoto, H., Hakozaki, M., Nabeshima, K., Iwamoto, Y., Oda, Y., 2017. Phosphorylation of STAT3 in undifferentiated pleomorphic sarcoma is correlated with a favorable prognosis. Pathobiology 84, 161-169. Blagburn, B.L., Vaughan, J.L., Butler, J.M., Parks, S.C., 1999. Dose titration of an injectable formulation of lufenuron in cats experimentally infested with fleas. Am J Vet Res 60, 1513-1515. Bromberg, J.F., Wrzeszczynska, M.H., Devgan, G., Zhao, Y., Pestell, R.G., Albanese, C., Darnell, J.E., Jr., 1999. Stat3 as an oncogene. Cell 98, 295-303. Brown, M.E., Bear, M.D., Rosol, T.J., Premanandan, C., Kisseberth, W.C., London, C.A., 2015. Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinoma. BMC Vet Res 11, 206. Buracco, P., Martano, M., Morello, E., Ratto, A., 2002. Vaccine-associated-like fibrosarcoma at the site of a deep nonabsorbable suture in a cat. Vet J 163, 105-107. Carneiro, C.S., de Queiroz, G.F., Pinto, A.C., Dagli, M.L., Matera, J.M., 2018. Feline injection site sarcoma: immunohistochemical characteristics. J Feline Med Surg 4, 314-321. Cecco, B.S., Henker, L.C., De Lorenzo, C., Schwertz, C.I., Bianchi, R.M., da Costa, F.V.A., Driemeier, D., Pavarini, S.P., Sonne, L., 2019. Epidemiological and pathological characterization of feline injection site sarcomas in southern Brazil. J Comp Pathol 172, 31-36. Chiti, L.E., Martano, M., Ferrari, R., Boracchi, P., Giordano, A., Grieco, V., Buracco, P., Iussich, S., Giudice, C., Miniscalco, B., Zani, D.D., Proverbio, D., Morello, E., Stefanello, D., 2019. Evaluation of leukocyte counts and neutrophil-to-lymphocyte ratio as predictors of local recurrence of feline injection site sarcoma after curative intent surgery. Vet Comp Oncol 18, 105-116. Cohen, M., Wright, J.C., Brawner, W.R., Smith, A.N., Henderson, R., Behrend, E.N., 2001. Use of surgery and electron beam irradiation, with or without chemotherapy, for treatment of vaccine-associated sarcomas in cats: 78 cases (1996-2000). J Am Vet Med Assoc 219, 1582-1589. Couto, J.I., Bear, M.D., Lin, J., Pennel, M., Kulp, S.K., Kisseberth, W.C., London, C.A., 2012. Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines. BMC Vet Res 8, 244. Couto, S.S., Griffey, S.M., Duarte, P.C., Madewell, B.R., 2002. Feline vaccine-associated fibrosarcoma: morphologic distinctions. Vet Pathol 39, 33-41. Coyne, M.J., Reeves, N.C., Rosen, D.K., 1997. Estimated prevalence of injection-site sarcomas in cats during 1992. J Am Vet Med Assoc 210, 249-251. Daly, M.K., Saba, C.F., Crochik, S.S., Howerth, E.W., Kosarek, C.E., Cornell, K.K., Roberts, R.E., Northrup, N.C., 2008. Fibrosarcoma adjacent to the site of microchip implantation in a cat. J Feline Med Surg 10, 202-205. Darby, I.A., Zakuan, N., Billet, F., Desmouliere, A., 2016. The myofibroblast, a key cell in normal and pathological tissue repair. Cell Mol Life Sci 73, 1145-1157. Dennis, M.M., McSporran, K.D., Bacon, N.J., Schulman, F.Y., Foster, R.A., Powers, B.E., 2011. Prognostic factors for cutaneous and subcutaneous soft tissue sarcomas in dogs. Vet Pathol 48, 73-84. Doddy, F.D., Glickman, L.T., Glickman, N.W., Janovitz, E.B., 1996. Feline fibrosarcomas at vaccination sites and non-vaccination sites. J Comp Pathol 114, 165-174. Dubielzig, R.R., Everitt, J., Shadduck, J.A., Albert, D.M., 1990. Clinical and morphologic features of post-traumatic ocular sarcomas in cats. Vet Pathol 27, 62-65. Eckstein, C., Guscetti, F., Roos, M., Martin de las Mulas, J., Kaser-Hotz, B., Rohrer Bley, C., 2009. A retrospective analysis of radiation therapy for the treatment of feline vaccine-associated sarcoma. Vet Comp Oncol 7, 54-68. Fagard, R., Metelev, V., Souissi, I., Baran-Marszak, F., 2013. STAT3 inhibitors for cancer therapy: Have all roads been explored? JAKSTAT 2, e22882. Fang, P., Hwa, V., Rosenfeld, R.G., 2006. Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway. Exp Cell Res 312, 1229-1239. Furqan, M., Akinleye, A., Mukhi, N., Mittal, V., Chen, Y., Liu, D., 2013. STAT inhibitors for cancer therapy. J Hematol Oncol 6, 90. German, A.J., Hall, E.J., Day, M.J., 2003. Chronic intestinal inflammation and intestinal disease in dogs. J Vet Intern Med 17, 8-20. Giudice, C., Stefanello, D., Sala, M., Cantatore, M., Russo, F., Romussi, S., Travetti, O., Di Giancamillo, M., Grieco, V., 2010. Feline injection-site sarcoma: recurrence, tumour grading and surgical margin status evaluated using the three-dimensional histological technique. Vet J 186, 84-88. Grivennikov, S.I., Karin, M., 2010. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21, 11-19. Gobar, G.M., Kass, P.H., 2002. World wide web-based survey of vaccination practices, postvaccinal reactions, and vaccine site-associated sarcomas in cats. J Am Vet Med Assoc 220, 1477-1482. Greten, F.R., Eckmann, L., Greten, T.F., Park, J.M., Li, Z.W., Egan, L.J., Kagnoff, M.F., Karin, M., 2004. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285-296. Gu, L., Talati, P., Vogiatzi, P., Romero-Weaver, A.L., Abdulghani, J., Liao, Z., Leiby, B., Hoang, D.T., Mirtti, T., Alanen, K., Zinda, M., Huszar, D., Nevalainen, M.T., 2014. Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. Mol Cancer Ther 13, 1246-1258. Hahn, K.A., Endicott, M.M., King, G.K., Harris-King, F.D., 2007. Evaluation of radiotherapy alone or in combination with doxorubicin chemotherapy for the treatment of cats with incompletely excised soft tissue sarcomas: 71 cases (1989-1999). J Am Vet Med Assoc 231, 742-745. Harbison, M.L., Godleski, J.J., 1983. Malignant mesothelioma in urban dogs. Vet Pathol 20, 531-540. He, G., Karin, M., 2011. NF-kappaB and STAT3 - key players in liver inflammation and cancer. Cell Res 21, 159-168. Hendrick, M.J., 1999. Feline vaccine-associated sarcomas. Cancer Invest 17, 273-277. Hendrick, M.J., Brooks, J.J., 1994. Postvaccinal sarcomas in the cat: histology and immunohistochemistry. Vet Pathol 31, 126-129. Hendrick, M.J., Goldschmidt, M.H., 1991. Do injection site reactions induce fibrosarcomas in cats? J Am Vet Med Assoc 199, 968. Hendrick, M.J., Goldschmidt, M.H., Shofer, F.S., Wang, Y.Y., Somlyo, A.P., 1992. Postvaccinal sarcomas in the cat: epidemiology and electron probe microanalytical identification of aluminum. Cancer Res 52, 5391-5394. Hershey, A.E., Sorenmo, K.U., Hendrick, M.J., Shofer, F.S., Vail, D.M., 2000. Prognosis for presumed feline vaccine-associated sarcoma after excision: 61 cases (1986-1996). J Am Vet Med Assoc 216, 58-61. Hsueh, C.S., Wu, C.H., Shih, C.H., Yeh, J.L., Jeng, C.R., Pang, V.F., Chiou, H.Y., Chang, H.W., 2019. Role of nuclear factor-kappa B in feline injection site sarcoma. BMC Vet Res 15, 365. Hughes, K., Scase, T.J., Foote, A.K., 2015. Estrogen receptor and signal transducer and activator of transcription 3 expression in equine mammary tumors. Vet Pathol 52, 631-634. Hughes, K., Scott, V.H.L., Blanck, M., Barnett, T.P., Spanner Kristiansen, J., Foote, A.K., 2018. Equine renal hemangiosarcoma: clinical presentation, pathologic features, and pSTAT3 expression. J Vet Diagn Invest 30, 268-274. Hussain, S.P., Harris, C.C., 2007. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 121, 2373-2380. Huynh, J., Chand, A., Gough, D., Ernst, M., 2019. Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map. Nat Rev Cancer 19, 82-96. Jacobs, T.M., Poehlmann, C.E., Kiupel, M., 2017. Injection-site sarcoma in a dog: clinical and pathological findings. Case Rep Vet Med 2017, 6952634. Ji, K., Zhang, L., Zhang, M., Chu, Q., Li, X., Wang, W., 2016. Prognostic value and clinicopathological significance of p-stat3 among gastric carcinoma patients: a systematic review and meta-analysis. Medicine 95, e2641. Jourdier, T.M., Moste, C., Bonnet, M.C., Delisle, F., Tafani, J.P., Devauchelle, P., Tartaglia, J., Moingeon, P., 2003. Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2). Gene Ther 10, 2126-2132. Kalisperati, P., Spanou, E., Pateras, I.S., Korkolopoulou, P., Varvarigou, A., Karavokyros, I., Gorgoulis, V.G., Vlachoyiannopoulos, P.G., Sougioultzis, S., 2017. Inflammation, DNA damage, Helicobacter pylori and gastric tumorigenesis. Front Genet 8, 20. Kang, S., Southard, T., Hume, K.R., 2017. DNA damage is a feature of feline injection-site sarcoma. Vet Comp Oncol 15, 518-524. Kass, P.H., Barnes, W.G., Jr., Spangler, W.L., Chomel, B.B., Culbertson, M.R., 1993. Epidemiologic evidence for a causal relation between vaccination and fibrosarcoma tumorigenesis in cats. J Am Vet Med Assoc 203, 396-405. Kass, P.H., Spangler, W.L., Hendrick, M.J., McGill, L.D., Esplin, D.G., Lester, S., Slater, M., Meyer, E.K., Boucher, F., Peters, E.M., Gobar, G.G., Htoo, T., Decile, K., 2003. Multicenter case-control study of risk factors associated with development of vaccine-associated sarcomas in cats. J Am Vet Med Assoc 223, 1283-1292. Katayama, R., Huelsmeyer, M.K., Marr, A.K., Kurzman, I.D., Thamm, D.H., Vail, D.M., 2004. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. Cancer Chemother Pharmacol 54, 25-33. Khan, S.G., Bickers, D.R., Mukhtar, H., Agarwal, R., 1994. Ras p21 farnesylation in ultraviolet B radiation-induced tumors in the skin of SKH-1 hairless mice. J Invest Dermatol 102, 754-758. Kliczkowska, K., Jankowska, U., Jagielski, D., Czopowicz, M., Sapierzynski, R., 2015. Epidemiological and morphological analysis of feline injection site sarcomas. Pol J Vet Sci 18, 313-322. Kobayashi, T., Hauck, M.L., Dodge, R., Page, R.L., Price, G.S., Williams, L.E., Hardie, E.M., Mathews, K.G., Thrall, D.E., 2002. Preoperative radiotherapy for vaccine associated sarcoma in 92 cats. Vet Radiol Ultrasound 43, 473-479. Kong, X., Sun, T., Kong, F., Du, Y., Li, Z., 2014. Chronic pancreatitis and pancreatic cancer. Gastrointest Tumors 1, 123-134. Lesinski, G.B., Anghelina, M., Zimmerer, J., Bakalakos, T., Badgwell, B., Parihar, R., Hu, Y., Becknell, B., Abood, G., Chaudhury, A.R., Magro, C., Durbin, J., Carson, W.E., 3rd, 2003. The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. J Clin Invest 112, 170-180. Levy, D.E., Lee, C.K., 2002. What does Stat3 do? J Clin Invest 109, 1143-1148. Li, M.X., Bi, X.Y., Huang, Z., Zhao, J.J., Han, Y., Li, Z.Y., Zhang, Y.F., Li, Y., Chen, X., Hu, X.H., Zhao, H., Cai, J.Q., 2015. Prognostic role of phospho-STAT3 in patients with cancers of the digestive system: a systematic review and meta-analysis. PLoS One 10, e0127356. Lin, L., Hutzen, B., Li, P.K., Ball, S., Zuo, M., DeAngelis, S., Foust, E., Sobo, M., Friedman, L., Bhasin, D., Cen, L., Li, C., Lin, J., 2010. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia 12, 39-50. Linder, B., Weirauch, U., Ewe, A., Uhmann, A., Seifert, V., Mittelbronn, M., Harter, P.N., Aigner, A., Kogel, D., 2019. Therapeutic targeting of Stat3 using lipopolyplex nanoparticle-formulated siRNA in a syngeneic orthotopic mouse glioma model. Cancers (Basel) 11, 333. Liu, L., McBride, K.M., Reich, N.C., 2005. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. Proc Natl Acad Sci U S A 102, 8150-8155. Lu, H., Ouyang, W., Huang, C., 2006. Inflammation, a key event in cancer development. Mol Cancer Res 4, 221-233. Macha, M.A., Matta, A., Kaur, J., Chauhan, S.S., Thakar, A., Shukla, N.K., Gupta, S.D., Ralhan, R., 2011. Prognostic significance of nuclear pSTAT3 in oral cancer. Head Neck 33, 482-489. Macy, D.W., Hendrick, M.J., 1996. The potential role of inflammation in the development of postvaccinal sarcomas in cats. Vet Clin North Am Small Anim Pract 26, 103-109. Madewell, B.R., Griffey, S.M., McEntee, M.C., Leppert, V.J., Munn, R.J., 2001. Feline vaccine-associated fibrosarcoma: an ultrastructural study of 20 tumors (1996-1999). Vet Pathol 38, 196-202. Mandell, J.W., 2008. Immunohistochemical assessment of protein phosphorylation state: the dream and the reality. Histochem Cell Biol 130, 465-471. Mantovani, A., Allavena, P., Sica, A., Balkwill, F., 2008. Cancer-related inflammation. Nature 454, 436-444. Martano, M., Morello, E., Buracco, P., 2011. Feline injection-site sarcoma: past, present and future perspectives. Vet J 188, 136-141. Martano, M., Morello, E., Iussich, S., Buracco, P., 2012. A case of feline injection-site sarcoma at the site of cisplatin injections. J Feline Med Surg 14, 751-754. Martano, M., Morello, E., Ughetto, M., Iussich, S., Petterino, C., Cascio, P., Buracco, P., 2005. Surgery alone versus surgery and doxorubicin for the treatment of feline injection-site sarcomas: a report on 69 cases. Vet J 170, 84-90. Mayer, M.N., Treuil, P.L., LaRue, S.M., 2009. Radiotherapy and surgery for feline soft tissue sarcoma. Vet Radiol Ultrasound 50, 669-672. Mills, S.W., Musil, K.M., Davies, J.L., Hendrick, S., Duncan, C., Jackson, M.L., Kidney, B., Philibert, H., Wobeser, B.K., Simko, E., 2015. Prognostic value of histologic grading for feline mammary carcinoma: a retrospective survival analysis. Vet Pathol 52, 238-249. Morrison, W.B., 2012. Inflammation and cancer: a comparative view. J Vet Intern Med 26, 18-31. Morrison, W.B., Starr, R.M., Vaccine-associated feline sarcomas. J Am Vet Med Assoc 218, 697-702. Multhoff, G., Molls, M., Radons, J., 2011. Chronic inflammation in cancer development. Front Immunol 2, 98. Munday, J.S., Banyay, K., Aberdein, D., French, A.F., 2011. Development of an injection site sarcoma shortly after meloxicam injection in an unvaccinated cat. J Feline Med Surg 13, 988-991. Murakami, T., Takigawa, N., Ninomiya, T., Ochi, N., Yasugi, M., Honda, Y., Kubo, T., Ichihara, E., Hotta, K., Tanimoto, M., Kiura, K., 2014. Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model. Lung Cancer 83, 30-36. Murray, J., 1998. Vaccine injection-site sarcoma in a ferret. J Am Vet Med Assoc 213, 955. Nieto, A., Sanchez, M.A., Martinez, E., Rollan, E., 2003. Immunohistochemical expression of p53, fibroblast growth factor-b, and transforming growth factor-alpha in feline vaccine-associated sarcomas. Vet Pathol 40, 651-658. Nolan, M.W., Griffin, L.R., Custis, J.T., LaRue, S.M., 2013. Stereotactic body radiation therapy for treatment of injection-site sarcomas in cats: 11 cases (2008-2012). J Am Vet Med Assoc 243, 526-531. Odate, S., Veschi, V., Yan, S., Lam, N., Woessner, R., Thiele, C.J., 2017. Inhibition of STAT3 with the generation 2.5 antisense oligonucleotide, AZD9150, decreases neuroblastoma tumorigenicity and increases chemosensitivity. Clin Cancer Res 23, 1771-1784. Ouedraogo, Z.G., Muller-Barthelemy, M., Kemeny, J.L., Dedieu, V., Biau, J., Khalil, T., Raoelfils, L.I., Granzotto, A., Pereira, B., Beaudoin, C., Guissou, I.P., Berger, M., Morel, L., Chautard, E., Verrelle, P., 2016. STAT3 serine 727 phosphorylation: a relevant target to radiosensitize human glioblastoma. Brain Pathol 26, 18-30. Pectasides, E., Egloff, A.M., Sasaki, C., Kountourakis, P., Burtness, B., Fountzilas, G., Dafni, U., Zaramboukas, T., Rampias, T., Rimm, D., Grandis, J., Psyrri, A., 2010. Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. Clin Cancer Res 16, 2427-2434. Petterino, C., Martano, M., Cascio, P., Cerruti, F., Martini, M., Morello, E., Bruno, R., Castagnaro, M., Buracco, P., 2006a. Immunohistochemical study of STAT3 expression in feline injection-site fibrosarcomas. J Comp Pathol 134, 91-100. Petterino, C., Ratto, A., Arcicasa, E., Podesta, G., Drigo, M., Pellegrino, C., 2006b. Expression of Stat3 in feline mammary gland tumours and its relation to histological grade. Vet Res Commun 30, 599-611. Pikarsky, E., Porat, R.M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., Ben-Neriah, Y., 2004. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431, 461-466. Porcellato, I., Menchetti, L., Brachelente, C., Sforna, M., Reginato, A., Lepri, E., Mechelli, L., 2017. Feline injection-site sarcoma. Vet Pathol 54, 204-211. Romanelli, G., Marconato, L., Olivero, D., Massari, F., Zini, E., 2008. Analysis of prognostic factors associated with injection-site sarcomas in cats: 57 cases (2001-2007). J Am Vet Med Assoc 232, 1193-1199. Saba, C.F., 2017. Vaccine-associated feline sarcoma: current perspectives. Vet Med (Auckl) 8, 13-20. Sakaguchi, M., Oka, M., Iwasaki, T., Fukami, Y., Nishigori, C., 2012. Role and regulation of STAT3 phosphorylation at Ser727 in melanocytes and melanoma cells. J Invest Dermatol 132, 1877-1885. Santelices Iglesias, O.A., Wright, C., Duchene, A.G., Risso, M.A., Risso, P., Zanuzzi, C.N., Nishida, F., Lavid, A., Confente, F., Diaz, M., Portiansky, E.L., Gimeno, E.J., Barbeito, C.G., 2018. Association between degree of anaplasia and degree of inflammation with the expression of COX-2 in feline injection site sarcomas. J Comp Pathol 165, 45-51. Schindler, C., Levy, D.E., Decker, T., 2007. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 282, 20059-20063. Sen, M., Thomas, S.M., Kim, S., Yeh, J.I., Ferris, R.L., Johnson, J.T., Duvvuri, U., Lee, J., Sahu, N., Joyce, S., Freilino, M.L., Shi, H., Li, C., Ly, D., Rapireddy, S., Etter, J.P., Li, P.K., Wang, L., Chiosea, S., Seethala, R.R., Gooding, W.E., Chen, X., Kaminski, N., Pandit, K., Johnson, D.E., Grandis, J.R., 2012. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov 2, 694-705. Setsu, N., Kohashi, K., Endo, M., Yamamoto, H., Tamiya, S., Takahashi, Y., Yamada, Y., Ishii, T., Matsuda, S., Yokoyama, R., Iwamoto, Y., Oda, Y., 2013. Phosphorylation of signal transducer and activator of transcription 3 in soft tissue leiomyosarcoma is associated with a better prognosis. Int J Cancer 132, 109-115. Sgrignani, J., Garofalo, M., Matkovic, M., Merulla, J., Catapano, C.V., Cavalli, A., 2018. Structural biology of STAT3 and its implications for anticancer therapies development. Int J Mol Sci 19. Shaw, S.C., Kent, M.S., Gordon, I.K., Collins, C.J., Greasby, T.A., Beckett, L.A., Hammond, G.M., Skorupski, K.A., 2009. Temporal changes in characteristics of injection-site sarcomas in cats: 392 cases (1990-2006). J Am Vet Med Assoc 234, 376-380. Shuai, K., Liu, B., 2005. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol 5, 593-605. Tong, M., Wang, J., Jiang, N., Pan, H., Li, D., 2017. Correlation between p-STAT3 overexpression and prognosis in lung cancer: A systematic review and meta-analysis. PLOS ONE 12, e0182282. Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., De Groot, R.P., Jove, R., 1998. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 18, 2545-2552. Turkson, J., Zhang, S., Palmer, J., Kay, H., Stanko, J., Mora, L.B., Sebti, S., Yu, H., Jove, R., 2004. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 3, 1533-1542. Wei, S., Henderson-Jackson, E., Qian, X., Bui, M.M., 2017. Soft Tissue Tumor Immunohistochemistry update: illustrative examples of diagnostic pearls to avoid pitfalls. Arch Pathol Lab Med 141, 1072-1091. Wilcock, B., Wilcock, A., Bottoms, K., 2012. Feline postvaccinal sarcoma: 20 years later. Can Vet J 53, 430-434. Williams, L.E., Banerji, N., Klausner, J.S., Kapur, V., Kanjilal, S., 2001. Establishment of two vaccine-associated feline sarcoma cell lines and determination of in vitro chemosensitivity to doxorubicin and mitoxantrone. Am J Vet Res 62, 1354-1357. Wong, A.L., Soo, R.A., Tan, D.S., Lee, S.C., Lim, J.S., Marban, P.C., Kong, L.R., Lee, Y.J., Wang, L.Z., Thuya, W.L., Soong, R., Yee, M.Q., Chin, T.M., Cordero, M.T., Asuncion, B.R., Pang, B., Pervaiz, S., Hirpara, J.L., Sinha, A., Xu, W.W., Yuasa, M., Tsunoda, T., Motoyama, M., Yamauchi, T., Goh, B.C., 2015. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol 26, 998-1005. Wood, C., Scott, E.M., 2019. Feline ocular post-traumatic sarcomas: Current understanding, treatment and monitoring. J Feline Med Surg 21, 835-842. Woodward, K.N., 2011. Origins of injection-site sarcomas in cats: the possible role of chronic inflammation-a review. ISRN Vet Sci 2011, 210982. Yang, J., Chatterjee-Kishore, M., Staugaitis, S.M., Nguyen, H., Schlessinger, K., Levy, D.E., Stark, G.R., 2005. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 65, 939-947. Yang, S.F., Wang, S.N., Wu, C.F., Yeh, Y.T., Chai, C.Y., Chunag, S.C., Sheen, M.C., Lee, K.T., 2007. Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma. J Clin Pathol 60, 642-648. Yu, H., Jove, R., 2004. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer 4, 97-105. Yu, H., Kortylewski, M., Pardoll, D., 2007. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7, 41-51. Yu, H., Lee, H., Herrmann, A., Buettner, R., Jove, R., 2014. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 14, 736-746. Zabielska-Koczywas, K., Wojtalewicz, A., Lechowski, R., 2017. Current knowledge on feline injection-site sarcoma treatment. Acta Vet Scand 59, 47. Zeiss, C.J., Johnson, E.M., Dubielzig, R.R., 2003. Feline intraocular tumors may arise from transformation of lens epithelium. Vet Pathol 40, 355-362. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/54627 | - |
| dc.description.abstract | 貓注射部位肉瘤（Feline injection site sarcomas; FISSs）為組織型態多樣的間質來源惡性腫瘤，最早在1990年代因與含鋁佐劑之狂犬病和貓白血病疫苗之使用有高度相關性而被注意到。目前普遍認為FISS的致病機轉與注射或異物引起之慢性炎症有關。慢性炎症會促進細胞激素及生長因子的分泌與轉錄因子的活化，進而促使纖維母細胞與肌纖維母細胞的增生與腫瘤化。在眾多與慢性炎症相關的轉錄因子中，信號轉導及轉錄激活蛋白3（STAT3）在致腫瘤上扮演了舉足輕重的角色。人類醫學的研究中顯示，有近百分之七十的實質固態腫瘤與血液腫瘤其JAK-STAT3信號傳送路徑呈顯著活化，而STAT3信號傳送路徑可調控腫瘤細胞的增殖、存活及轉移與血管新生。本研究首先以免疫組織化學染色（immunohistochemitry; IHC）探討福馬林固定和石蠟包埋的FISS組織中，STAT3與磷酸化型STAT3之表現情形，結果證實有88.9％（40/45）的樣本呈現腫瘤細胞細胞質內STAT3陽性反應，53.3%（24/45）的樣本呈現磷酸化型STAT3腫瘤細胞細胞核內陽性反應。為了進一步探討STAT3之表現在貓疫苗注射部位肉瘤之角色，本研究使用兩個來自不同貓隻之FISS初代細胞株，並以STAT3抑制劑5-hydroxy-9,10-dioxo-9,10-dihydroanthracene-1-sulfonamide （LLL12）證實在STAT3磷酸化路徑受抑制下，FISS初代細胞之增殖與移行能力具劑量依賴性之顯著下降。由此可知STAT3在FISS之致腫瘤機制中扮演重要角色，在腫瘤的治療策略上，STAT3抑制劑可能具有臨床應用潛力。 | zh_TW |
| dc.description.abstract | Feline injection site sarcomas (FISSs) are malignant mesenchymal tumors of different histotypes and have been correlated with immunization of aluminum adjuvanted rabies and feline leukemia virus (FeLV) vaccines since 1990s. The pathogenesis of FISS has been correlated with chronic inflammation induced by injection or foreign materials, resulting in proliferation and ultimately neoplastic transformation of fibroblasts and myofibroblasts through upregulation of multiple cytokines, growth factors, and transcription factors. Activation of the Janus Kinase (JAK)-signal transducer and activator of transcription 3 (STAT3) has been described in nearly 70% of solid and hematological tumors in humans. The STAT3 signaling has been demonstrated to play a critical role in tumor development by regulating signaling pathways involved in cell proliferation, survival, metastasis, and angiogenesis. To characterize the role of STAT3 in FISS, we first detected STAT3 and phosphorylated STAT3 in formalin-fixed and paraffin- embedded (FFPE) FISS tissues by immunohistochemistry. The STAT3 was detected in 88.9% (40/45) of FISS cases and the phosphorylated STAT3 was detected in 53.3% (24/45) of FISS cases. However, both were not correlated with tumor grading. Two primary cells derived from the FISSs of two cats exhibiting consistent immunophenotypes with their parental FFPE tissues were established. A dose-dependent inhibitory effect on the cell proliferation and cell migration was observed in both primary FISS cells treated with the STAT3 inhibitor, 5-hydroxy-9,10-dioxo-9,10-dihydroanthracene-1-sulfonamide (LLL12). The high expression rate of STAT3 in FISS cases and the dose-dependent inhibitory effect on the growth of FISS primary cells treated with STAT3 inhibitor suggest that STAT3 may play an important role in the tumorigenesis of FISS and be a potential molecular therapeutic target for FISS. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T03:35:58Z (GMT). No. of bitstreams: 1 U0001-3003202117260300.pdf: 2854476 bytes, checksum: 03d24586caf8feec404e3d005f17a7a1 (MD5) Previous issue date: 2021 | en |
| dc.description.tableofcontents | 口試委員會審定書 # 中文摘要 i Abstract ii Contents iv List of tables vii List of figures viii Chapter 1 Introduction 9 1.1 History of feline injection site sarcoma (FISS) 9 1.2 Epidemiology 10 1.3 Etiology 11 1.4 Pathogenesis 12 1.4.1 Possible role of chronic inflammation 12 1.4.2 Critical mediators link chronic inflammation to neoplasia 15 1.4.3 What does STAT3 do? 16 1.4.4 STAT3 structure, activation, and oncogenesis 17 1.5 Clinical behavior of FISSs 20 1.6 Pathology of FISSs 20 1.6.1 Gross morphology 20 1.6.2 Histological features 21 1.6.3 Immunohistochemistry 22 1.7 Diagnosis 22 1.8 Treatment 23 1.8.1 Current treatment and prognosis 23 1.8.2 STAT3 as a therapeutic target 25 1.9 Aim of the study 27 1.10 Experimental design 28 Chapter 2 Materials and methods 29 2.1 Case collection 29 2.2 Immunohistochemical staining for FFPE tissues 29 2.3 Histopathological and immunohistochemistry scoring criteria 30 2.4 Primary FISS cells isolation and cultivation 31 2.5 Validation of antibodies 32 2.5.1 Preparation of primary FISS cell lysates 33 2.5.2 Western blotting 33 2.6 Immunocytochemistry staining for FISS cells 34 2.7 Reagents 35 2.8 Cell proliferation 35 2.9 Cell migration 37 2.10 Statistical analysis 37 Chapter 3 Results 39 3.1 Detection of STAT3 and phospho-STAT3 (Tyr705) expression and their correlation with histopathological grading in FISS cells by IHC 39 3.2 Correlation of the immunophenotypes of the primary FISS cells with their corresponding FFPE samples 39 3.3 STAT3 inhibitor (LLL12) inhibits the proliferation of FISS cells with a dose-dependent effect 40 3.4 Inhibition of the migration of FISS primary cells by LLL12 using the wound healing assay 41 Chapter 4 Discussion 43 4.1 Retrospective histopathological studies 43 4.1.1 Expression patterns of STAT3 and phospho-STAT3 (Tyr705) in FISSs 43 4.1.2 The correlations of expressions of STAT3 and phospho-STAT3 (Tyr705) with tumor grading in FISSs 45 4.1.3 The immunophenotype of FISS cells and their derived FFPE tissues 45 4.2 In vitro studies 47 Chapter 5 Conclusion 50 Chapter 6 Future works 51 6.1 Prognostic significance of phospho-STAT3 (Tyr705) in FISSs 51 6.2 The effect of LLL12 on STAT3-dependent transcriptional activities in FISS cells 51 6.3 Antitumor functional assays in FISS cells 52 References 67 | |
| dc.language.iso | zh-TW | |
| dc.title | 探討信號轉導及轉錄激活蛋白3於貓注射部位肉瘤之角色 | zh_TW |
| dc.title | Investigation of the Role of Signal Transducer and Activator of Transcription 3 (STAT3) in Feline Injection Site Sarcoma | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 109-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 張晏禎(Yen-Chen Chang),鄭謙仁(Chian-Ren Jeng),邱慧英(Hue-Ying Chiou),高啟霏(Chi-Fei Kao),龎飛(Victor Fei Pang) | |
| dc.subject.keyword | 貓注射部位肉瘤,慢性炎症,信號轉導及轉錄激活蛋白3, | zh_TW |
| dc.subject.keyword | Feline injection site sarcoma,Chronic inflammation,STAT3, | en |
| dc.relation.page | 80 | |
| dc.identifier.doi | 10.6342/NTU202100811 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2021-03-31 | |
| dc.contributor.author-college | 獸醫專業學院 | zh_TW |
| dc.contributor.author-dept | 分子暨比較病理生物學研究所 | zh_TW |
| 顯示於系所單位： | 分子暨比較病理生物學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-3003202117260300.pdf 目前未授權公開取用 | 2.79 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。